CollPlant - רווח נקי למניה ב-12 החודשים האחרונים CLGN

The year-over-year EPS growth dynamics over a rolling period reflect market expectations, where 16.50 serves as the baseline parameter value. CollPlant Biotechnologies (CLGN) generates revenue from the production of collagen derived from modified tobacco, which ensures high margins. The Israeli startup develops hypoallergenic materials for 3D organ printing. Growth potential is driven by the rapid expansion of the transplantology and aesthetic surgery segments.

This indicator measures the dynamics of net earnings per share over a rolling year, smoothing quarterly volatility to identify real trends in return on assets. By analyzing the EPS growth rate over the last 12 months YoY, an investor assesses the margin stability of CollPlant Biotechnologies (CLGN) against significant costs for third-party clinical trials, which may slow the pace of final capital accumulation.